Starting May 14th, 2021, the data in will be frozen in preparation for the migration to the new Primo VE-powered LocatorPlus Catalog which goes live June 8th, 2021. See the Technical Bulletin article for more information. will remain available until August 31st, 2021.

Start Over
Detailed View
SearchTitlesLibrary InformationOther DatabasesHelpHome

Collections of the National Library of Medicine
Search Request: Simple Search = 101468743
Search Results: Displaying 1 of 1 records

Summary ViewDetailed ViewTable of ContentsMARC ViewMore Like This

Hydroxyurea : treatment for sickle cell disease / NIH.

Title: Hydroxyurea : treatment for sickle cell disease / NIH.
Variant Title: Treatment for sickle cell disease
Publisher: [Bethesda, Md. : National Institutes of Health, 2008]
Related Names: National Institutes of Health (U.S.)
Content Type: two-dimensional moving image
Media Type: computer
Carrier Type: online resource
Language: eng
Electronic Links:
MeSH Subjects: Anemia, Sickle Cell --complications
Anemia, Sickle Cell --drug therapy
Health Services Accessibility
Hydroxyurea --therapeutic use
Risk Assessment
United States
Consensus Development Conference, NIH
Summary: (CIT): NIH Consensus Development Conference Sickle cell disease is an inherited blood disorder that affects between 50,000 and 75,000 people in the United States, and is most common among people whose ancestors come from sub-Saharan Africa, South and Central America, the Middle East, India, and the Mediterranean basin. Sickle cell disease occurs when an infant inherits the gene for sickle hemoglobin from both parents (Hb SS, or sickle cell anemia), or the gene for sickle hemoglobin from one parent and another abnormal hemoglobin gene from the other parent. Each year, approximately 2,000 babies with sickle cell disease are born in the United States. The condition is chronic and lifelong, and is associated with a decreased lifespan. In addition, approximately 2 million Americans carry the sickle cell trait, which increases the public health burden as this disorder is passed on to future generations. The red blood cells in people with sickle cell disease become deoxygenated (or depleted of oxygen), and crescent-shaped or "sickled." The cells become sticky, and adhere to blood vessel walls, thereby blocking blood flow within limbs and organs. These changes lead to acute painful episodes, chronic pain, and chronic damage to the brain, heart, lungs, kidneys, liver, and spleen. Infections and lung disease are leading causes of death. Pain crises are responsible for most emergency room visits and hospitalizations of people with sickle cell disease. Standard treatments for acute pain crises include painkilling medications, fluid replacement, and oxygen. In the mid-1990s, researchers began investigating the potential of hydroxyurea to reduce the number and severity of pain crises in sickle cell patients. Hydroxyurea is in a class of anti-cancer drugs and it acts to increase the overall percentage of normally structured red blood cells in the circulation. By diluting the number of cells that "sickle," it may, if taken on a daily basis, reduce their damaging effects. Hydroxyurea was approved by the FDA for use in adults with sickle cell anemia in 1998. However, there are a number of unresolved issues about the use of hydroxyurea, including a lack of knowledgeable providers who treat sickle cell disease, and patient and practitioner questions about safety and effectiveness, including concerns regarding potential long-term carcinogenesis.
Notes: Title from screen banner (viewed June 4, 2008).
Streaming video (13 hr., 57 min. : sd., col.).
NLM Unique ID: 101468743
Other ID Numbers: (DNLM)CIT:14322


Options for Print, Save or E-mail
Select Download Format:
E-mail Full record(s) to:

SearchTitlesLibrary InformationOther DatabasesHelpHome

Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services
Contact NLM